Furthermore, TCGA analysis also revealed that mRNA levels of KDM4B were significantly lower in various tumors compared to paired normal tissues, including skin cutaneous melanoma (SKCM), ovarian serous cystadenocarcinoma (OV), thyroid carcinoma (THCA), and cervical squamous cell carcinoma (CESC) (Fig. 3E), whereas slightly downregulated in the colorectal cancer (COAD) (Fig. S3B), suggesting that downregulated KDM4B results in cGAS inactivation and immune escape during tumor progression. This evidence concerns the gene KDM4B and ovarian serous cystadenocarcinoma.